Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription

Articles published in Eur J Dermatol

Retrieve available abstracts of 70 articles:
HTML format

Single Articles

    April 2021
  1. SCARD C, Nguyen JM, Varey E, Moustaghfir I, et al
    Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels.
    Eur J Dermatol. 2021 Apr 2. pii: ejd.2021.4009. doi: 10.1684/ejd.2021.4009.
    PubMed     Abstract available

    March 2021
  2. MILLAN-ESTEBAN D, Garcia-Casado Z, Manrique-Silva E, Viros A, et al
    Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients.
    Eur J Dermatol. 2021 Mar 1. pii: ejd.2021.3971. doi: 10.1684/ejd.2021.3971.
    PubMed     Abstract available

    February 2021
  3. RUSSO I, Filoni A, Alaibac M
    Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
    Eur J Dermatol. 2021 Feb 12. pii: ejd.2020.3958. doi: 10.1684/ejd.2020.3958.

    December 2020
  4. LUDWIG SV, F Cheng P, Mangana J, Braun R, et al
    Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis.
    Eur J Dermatol. 2020;30:699-709.
    PubMed     Abstract available

    November 2020
  5. MORA-FERNANDEZ V, Boada A, Manzano JL, Jaka A, et al
    Locally advanced head and neck squamous cell carcinoma and melanoma simultaneously treated with pembrolizumab: an unusual situation.
    Eur J Dermatol. 2020 Nov 24. pii: ejd.2020.3911. doi: 10.1684/ejd.2020.3911.

    October 2020
  6. GRAN F, Weber J, Schummer P, Kneitz H, et al
    Sarcoidosis developing upon immune checkpoint inhibition in advanced uveal melanoma.
    Eur J Dermatol. 2020;30:629-631.

    September 2020
  7. OGATA D, Murakami T, Arai E, Tsuchida T, et al
    A case of malignant melanoma of the areola in a male patient.
    Eur J Dermatol. 2020 Sep 18. pii: ejd.2020.3865. doi: 10.1684/ejd.2020.3865.

    August 2020
  8. DALLE S, Varey E, Nguyen JM, Dupuy A, et al
    Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.
    Eur J Dermatol. 2020 Aug 19. pii: ejd.2020.3848. doi: 10.1684/ejd.2020.3848.
    PubMed     Abstract available

  9. GIAVINA-BIANCHI M, Giavina-Bianchi P, Sotto MN, Rodig S, et al
    Nodular primary cutaneous melanoma is associated with PD-L1 expression.
    Eur J Dermatol. 2020;30:352-357.
    PubMed     Abstract available

    February 2020
  10. GRAN F, Emmerich K, Mohme S, Goebeler M, et al
    Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
    Eur J Dermatol. 2020;30:72-73.

    December 2019
  11. NIIJIMA Y, Ishitsuka Y, Inoue S, Maruyama H, et al
    Reconstruction using a vertical "sagging cheek" advancement flap for defects following full-thickness excision of non-melanoma skin cancer in the elderly: a case series.
    Eur J Dermatol. 2019;29:654-656.

  12. EL KHOURY R, Michael-Jubeli R, Bakar J, Dakroub H, et al
    Origanum essential oils reduce the level of melanin in B16-F1 melanocytes.
    Eur J Dermatol. 2019;29:596-602.
    PubMed     Abstract available

    October 2019
  13. BASSET SEGUIN N, Malvehy J, Nadal F, Creancier L, et al
    Risk behaviour and patient preferences for an improved non-melanoma skin cancer prevention modality for organ-transplanted patients; a European, multi-country, online patient community study.
    Eur J Dermatol. 2019 Oct 23. pii: ejd.2019.3639. doi: 10.1684/ejd.2019.3639.
    PubMed     Abstract available

  14. MOTEGI SI, Sekiguchi A, Toki S, Kishi C, et al
    Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Eur J Dermatol. 2019 Oct 16. pii: ejd.2019.3634. doi: 10.1684/ejd.2019.3634.
    PubMed     Abstract available

    June 2019
  15. ARIANAYAGAM S, Ieremia E, Matin RN
    Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Eur J Dermatol. 2019;29:349-351.

  16. BOCQUET-TREMOUREUX S, Scharbarg E, Nguyen JM, Varey E, et al
    Efficacy and safety of nivolumab in metastatic melanoma: real-world practice.
    Eur J Dermatol. 2019;29:315-321.
    PubMed     Abstract available

    April 2019
  17. SAMPOGNA F, Paradisi A, Iemboli ML, Ricci F, et al
    Comparison of quality of life between melanoma and non-melanoma skin cancer patients.
    Eur J Dermatol. 2019;29:185-191.
    PubMed     Abstract available

  18. ARACTINGI S, Pellacani G
    Computational neural network in melanocytic lesions diagnosis: artificial intelligence to improve diagnosis in dermatology?
    Eur J Dermatol. 2019;29.
    PubMed     Abstract available

  19. TAKIMOTO R, Honda T, Kataoka TR, Ueshima C, et al
    DIHS/DRESS-like eruption possibly induced by amoxicillin during treatment with nivolumab.
    Eur J Dermatol. 2019;29:228-229.

    February 2019
  20. GRAN F, Goebeler M, Gesierich A
    Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors.
    Eur J Dermatol. 2019;29:107-108.

    December 2018
  21. FRINGS VG, Goebeler M, Kneitz H
    Dermpath & Clinic: In situ melanoma arising within a speckled lentiginous nevus.
    Eur J Dermatol. 2018;28:857-859.

  22. GUTZMER R, Harrington KJ, Hoeller C, Lebbe C, et al
    Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
    Eur J Dermatol. 2018;28:736-749.
    PubMed     Abstract available

    November 2018
  23. MINOWA T, Kato J, Hida T, Horimoto K, et al
    Prognostic role of platelet to lymphocyte and lymphocyte to monocyte ratios in advanced melanoma treated with anti-programmed death-1.
    Eur J Dermatol. 2018 Nov 8. pii: ejd.2018.3381. doi: 10.1684/ejd.2018.3381.

    October 2018
  24. BREGEON B, Nguyen JM, Varey E, Quereux G, et al
    Positive margins after surgical excision of locoregional cutaneous melanoma metastasis and their impact on patient outcome.
    Eur J Dermatol. 2018 Oct 30. pii: ejd.2018.3402. doi: 10.1684/ejd.2018.3402.
    PubMed     Abstract available

  25. BEAUDOUX O, Riffaud L, Barbe C, Grange F, et al
    Prognostic factors and incidence of primary mucosal melanoma: a population-based study in France.
    Eur J Dermatol. 2018 Oct 30. pii: ejd.2018.3398. doi: 10.1684/ejd.2018.3398.
    PubMed     Abstract available

  26. DE CASTRO ARAUJO BL, Santos Thuler LC, De Melo AC
    Prognostic impact of tumescent local anaesthesia on survival and recurrence of melanoma following lymphadenectomy.
    Eur J Dermatol. 2018 Oct 23. pii: ejd.2018.3414. doi: 10.1684/ejd.2018.3414.

  27. SOARES AM, Szejnfeld VL, Enokihara MY, Michalany N, et al
    High serum 25-hydroxyvitamin D concentration in patients with a recent diagnosis of non-melanoma skin cancer: a case-control study.
    Eur J Dermatol. 2018 Oct 23. pii: ejd.2018.3401. doi: 10.1684/ejd.2018.3401.
    PubMed     Abstract available

  28. GAO HW, Tsai WC, Perng CL, Wang WM, et al
    Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
    Eur J Dermatol. 2018 Oct 15. pii: ejd.2018.3359. doi: 10.1684/ejd.2018.3359.
    PubMed     Abstract available

  29. FANIA L, Abeni D, Esposito I, Spagnoletti G, et al
    Increased incidence of cutaneous melanoma in organ transplant recipients based on a single-centre longitudinal study in Rome, Italy.
    Eur J Dermatol. 2018 Oct 15. pii: ejd.2018.3346. doi: 10.1684/ejd.2018.3346.

  30. NAKAMURA Y, Ishitsuka Y, Fujisawa Y, Konishi R, et al
    Pelvic reactive lymphadenopathy mimicking lymph node metastasis of heel malignant melanoma.
    Eur J Dermatol. 2018 Oct 15. pii: ejd.2018.3416. doi: 10.1684/ejd.2018.3416.

  31. YOKOTA K, Matsumoto T, Urata T, Goto K, et al
    The benefits of high-resolution, real-time colour-imaging of lymphatic flow for sentinel lymph node biopsy.
    Eur J Dermatol. 2018;28:680-681.

    August 2018
  32. STEMBRIDGE N, Davies A, Chan J, Todd P, et al
    Dermpath and Clinic: A red scaly lesion on the forearm.
    Eur J Dermatol. 2018;28:568-569.

    June 2018
  33. SAITO A, Fujisawa Y, Maruyama H, Nakamura Y, et al
    Subungual melanoma complicated by hydroxyurea-induced melanonychia with non-melanoma Hutchinson's sign.
    Eur J Dermatol. 2018 Jun 22. pii: ejd.2018.3345. doi: 10.1684/ejd.2018.3345.

  34. KOGAME T, Kaku Y, Endo Y, Yamashita C, et al
    A follow-up report of acral melanoma in a patient with Nagashima-type palmoplantar keratosis: validation of SERPINB7 mutation and local recurrence.
    Eur J Dermatol. 2018 Jun 11. pii: ejd.2018.3317. doi: 10.1684/ejd.2018.3317.

    April 2018
  35. OISO N, Sakai K, Yanagihara S, Nishio K, et al
    Genital mucosal melanoma with somatic SF3B1 R625C mutation.
    Eur J Dermatol. 2018 Apr 6. pii: ejd.2018.3281. doi: 10.1684/ejd.2018.3281.

  36. SILVA ESD, Tavares R, Paulitsch FDS, Zhang L, et al
    Use of sunscreen and risk of melanoma and non-melanoma skin cancer: a systematic review and meta-analysis.
    Eur J Dermatol. 2018 Apr 5. pii: ejd.2018.3251. doi: 10.1684/ejd.2018.3251.
    PubMed     Abstract available

  37. CHAPUT L, Laurent E, Pare A, Sallot A, et al
    One-step surgical removal of cutaneous melanoma with surgical margins based on preoperative ultrasound measurement of the thickness of the melanoma.
    Eur J Dermatol. 2018 Apr 5. pii: ejd.2018.3298. doi: 10.1684/ejd.2018.3298.
    PubMed     Abstract available

  38. KOFLER L, Breuninger H, Hafner HM, Schweinzer K, et al
    Lymph node dissection for melanoma using tumescence local anaesthesia: an observational study.
    Eur J Dermatol. 2018 Apr 5. pii: ejd.2018.3250. doi: 10.1684/ejd.2018.3250.
    PubMed     Abstract available

  39. ANSELMO LIMA C, Sampaio Lima M, Maria Da Silva A, Prado Nunes MA, et al
    Do cancer registries play a role in determining the incidence of non-melanoma skin cancers?
    Eur J Dermatol. 2018 Apr 5. pii: ejd.2018.3248. doi: 10.1684/ejd.2018.3248.
    PubMed     Abstract available

  40. MICANTONIO T, Neri L, Longo C, Grassi S, et al
    A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis.
    Eur J Dermatol. 2018;28:162-168.
    PubMed     Abstract available

    February 2018
  41. SHOBATAKE C, Miyagawa F, Ogawa K, Azukizawa H, et al
    Preoperative assessment of tumour thickness and vascularity using high-frequency ultrasonography in ten cases of cutaneous melanoma.
    Eur J Dermatol. 2018 Feb 5. pii: ejd.2018.3223. doi: 10.1684/ejd.2018.3223.

  42. TAKIMOTO R, Otsuka A, Kaku Y, Honda T, et al
    No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Eur J Dermatol. 2018 Feb 5. pii: ejd.2017.3151. doi: 10.1684/ejd.2017.3151.

  43. OYA K, Nakamura Y, Fujisawa Y, Endo R, et al
    Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Eur J Dermatol. 2018;28:129-130.

    January 2018
  44. FINON A, Zaragoza J, Maillard H, Beneton N, et al
    A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma.
    Eur J Dermatol. 2018 Jan 16. pii: ejd.2017.3167. doi: 10.1684/ejd.2017.3167.
    PubMed     Abstract available

    November 2017
  45. STEFANAKI C, Soura E, Plaka M, Chasapi V, et al
    A case series of paediatric and adolescent melanoma.
    Eur J Dermatol. 2017 Nov 27. pii: ejd.2017.3188. doi: 10.1684/ejd.2017.3188.

  46. COLOMBINO M, Paliogiannis P, Pagliarello C, Cossu A, et al
    Dermoscopy and confocal microscopy for metachronous multiple melanomas: morphological, clinical, and molecular correlations.
    Eur J Dermatol. 2017 Nov 27. pii: ejd.2017.3206. doi: 10.1684/ejd.2017.3206.
    PubMed     Abstract available

  47. FUKUMOTO T, Fujiwara S, Sakaguchi M, Oka M, et al
    A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
    Eur J Dermatol. 2017 Nov 24. pii: ejd.2017.3169. doi: 10.1684/ejd.2017.3169.

  48. RICCI F, Paradisi A, Maier SA, Kovacs M, et al
    Melanoma and tattoos: a case report and review of the literature.
    Eur J Dermatol. 2017 Nov 24. pii: ejd.2017.3184. doi: 10.1684/ejd.2017.3184.
    PubMed     Abstract available

  49. CUNHA N, Campos S, Serrao V
    Vitamin D levels in a cohort of Portuguese melanoma patients relate to time of follow-up from diagnosis, sun-exposure behaviour, and use of photoprotection.
    Eur J Dermatol. 2017 Nov 24. pii: ejd.2017.3161. doi: 10.1684/ejd.2017.3161.

  50. OGATA D, Uhara H, Tsutsumida A, Yamazaki N, et al
    Nail apparatus melanoma in a Japanese population: a comparative study of surgical procedures and prognoses in a large series of 151 cases.
    Eur J Dermatol. 2017 Nov 22. doi: 10.1684/ejd.2017.3133.
    PubMed     Abstract available

    October 2017
  51. KOMORI T, Otsuka A, Kusuba N, Taniguchi K, et al
    Rapid regression of metastatic brain tumours in a melanoma patient after dabrafenib/trametinib therapy.
    Eur J Dermatol. 2017;27:548-549.

  52. RUSSO I, Zorzetto L, Frigo AC, Chiarion Sileni V, et al
    A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience.
    Eur J Dermatol. 2017;27:482-486.
    PubMed     Abstract available

    September 2017
  53. BORIK L, Balagula Y, Hinds GA, Loss MJ, et al
    Non-melanoma skin cancers in African American solid organ transplant recipients: regional bias or a real need for surveillance?
    Eur J Dermatol. 2017 Sep 23. doi: 10.1684/ejd.2017.3059.

  54. TEJERA-VAQUERIZO A, Descalzo-Gallego MA, Traves V, Requena C, et al
    The intriguing effect of delay time to sentinel lymph node biopsy on survival: a propensity score matching study on a cohort of melanoma patients.
    Eur J Dermatol. 2017 Sep 23. doi: 10.1684/ejd.2017.3065.
    PubMed     Abstract available

    May 2017
  55. PARADISI A, Didona B, Tabolli S, Ricci F, et al
    Reduced frequency of non-melanoma skin cancer in 72,739 patients with psoriasis: a retrospective study.
    Eur J Dermatol. 2017 May 19. doi: 10.1684/ejd.2017.3032.
    PubMed     Abstract available

  56. BASSINO S, Ribero S, Miniotti M, Picardi A, et al
    Emotional distress and health-related quality of life among cutaneous melanoma follow-up outpatients: the role of self-perception of body image and surgical scarring.
    Eur J Dermatol. 2017 May 19. doi: 10.1684/ejd.2017.3048.

  57. DIKA E, Ravaioli GM, Fanti PA, Piraccini BM, et al
    Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study.
    Eur J Dermatol. 2017 May 19. doi: 10.1684/ejd.2017.3023.
    PubMed     Abstract available

  58. DIKA E, Fanti PA, Vaccari S, Capizzi E, et al
    Oestrogen and progesterone receptor in melanoma and nevi: an immunohistochemical study.
    Eur J Dermatol. 2017 May 19. doi: 10.1684/ejd.2017.3019.
    PubMed     Abstract available

  59. DRAGO F, Ciccarese G, Cogorno L, Calvi C, et al
    Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study.
    Eur J Dermatol. 2017 May 3. doi: 10.1684/ejd.2017.3025.
    PubMed     Abstract available

    March 2017
  60. VILDY S, Nguyen JM, Gaultier A, Knol AC, et al
    Impact of the time interval between lymph node recurrence and lymphadenectomy on melanoma patient survival.
    Eur J Dermatol. 2017 Mar 2. doi: 10.1684/ejd.2016.2955.
    PubMed     Abstract available

  61. TSUTSUMI R, Yoshida Y, Yamada N, Adachi K, et al
    Nagashima-type palmoplantar keratosis with melanoma: absence of epidermal Langerhans cells in hyperkeratotic skin.
    Eur J Dermatol. 2017 Mar 1. doi: 10.1684/ejd.2016.2960.

    February 2017
  62. THIERAUF J, Veit JA, Hess J, Treiber N, et al
    Checkpoint inhibition for advanced mucosal melanoma.
    Eur J Dermatol. 2017 Feb 3. doi: 10.1684/ejd.2016.2949.
    PubMed     Abstract available

    January 2017
  63. ASTRUA C, Fava P, Brizio M, Savoia P, et al
    A study of melanoma in Eastern European migrants in Italy.
    Eur J Dermatol. 2017 Jan 5. doi: 10.1684/ejd.2016.2950.
    PubMed     Abstract available

    December 2016
  64. OISHI K, Nakao M, Maeda S, Matsushita T, et al
    A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab.
    Eur J Dermatol. 2016 Dec 22. doi: 10.1684/ejd.2016.2943.

  65. ISHIKAWA K, Shono-Saito T, Yamate T, Kai Y, et al
    A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms.
    Eur J Dermatol. 2016.

  66. BETTI R, Moneghini L, Vergani R, Cerri A, et al
    Diagnostic performance parameters for melanocytic lesions before and during the dermoscopy era.
    Eur J Dermatol. 2016.

    November 2016
  67. FUKUMOTO T, Fujiwara S, Sakaguchi M, Oka M, et al
    Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo.
    Eur J Dermatol. 2016.

    September 2016
  68. FINK L, Amelio J, Harries M, Lebbe C, et al
    Making decisions on resectability and injectability status of lesions in the management of advanced melanoma in Germany, France and the UK.
    Eur J Dermatol. 2016.
    PubMed     Abstract available

    July 2016
  69. KUONEN F, Aschwanden J, Dimaio DJ, Elston DM, et al
    Colonisation of basal cell carcinoma by lentigo maligna: a case report, review of the literature, and series follow-up.
    Eur J Dermatol. 2016.
    PubMed     Abstract available

    June 2016
  70. CINOTTI E, Perrot JL, Labeille B, Biron AC, et al
    Skin tumours and skin aging in 209 French elderly people: the PROOF study.
    Eur J Dermatol. 2016.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.